ID

35785

Descrizione

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT02489968

collegamento

https://clinicaltrials.gov/show/NCT02489968

Keywords

versioni (1)
  1. 22/03/19 22/03/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

22 marzo 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Diabetes Mellitus, Type 2 NCT02489968

Inglese

Eligibility Diabetes Mellitus, Type 2 NCT02489968

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of type 2 diabetes prior to informed consent
Descrizione

Diabetes Mellitus, Non-Insulin-Dependent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011860
male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are:
Descrizione

Diet therapy | Exercise

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0012159
UMLS CUI [2]
C0015259
drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
Descrizione

Antidiabetics Absent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C0332197
pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of the maximum approved dose) on stable dosage for at least 12 weeks prior to the informed consent (for thiazolidinedione, therapy has to be unchanged for at least 18 weeks prior to the informed consent). individual antidiabetic drug will have to be discontinued at visit 1.
Descrizione

Antidiabetics Oral Quantity | Sulfonylurea | Antidiabetics Dose Stable | Thiazolidinediones unchanged | Antidiabetics Specific To be stopped

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0038766
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
UMLS CUI [4,1]
C1257987
UMLS CUI [4,2]
C0442739
UMLS CUI [5,1]
C0935929
UMLS CUI [5,2]
C0205369
UMLS CUI [5,3]
C1272691
haemoglobin a1c (hba1c) at visit 1 (screening)
Descrizione

Glycosylated hemoglobin A

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019018
for patients without antidiabetic therapy : hba1c >=8.0 to =<10.5%
Descrizione

Hemoglobin A1c measurement | Antidiabetics Absent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0474680
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C0332197
for patients with one oral antidiabetic drug : hba1c >=7.5 to =<10.5%
Descrizione

Hemoglobin A1c measurement | Antidiabetics Oral Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0474680
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C1265611
hba1c >=7.5 to =<10.0% at visit 4 for randomisation into the double blind treatment period
Descrizione

Hemoglobin A1c measurement | Randomization Double-Blind Method

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0474680
UMLS CUI [2,1]
C0034656
UMLS CUI [2,2]
C0013072
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
uncontrolled hyperglycaemia with a glucose level >270 mg/dl (>15.0 mmol/l) during the open label stabilisation period and placebo run in period
Descrizione

Hyperglycemia Uncontrolled | Glucose level

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020456
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0428548
impaired renal function, defined as estimated glomerular filtration rate (egfr) <45 ml/min/1.73m2 (modification of diet in renal disease (mdrd) formula)
Descrizione

Renal Insufficiency | Renal function GFR estimation by MDRD

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C2170215
acute coronary syndrome, stroke or transient ischemic attack (tia) within 12 weeks prior to informed consent
Descrizione

Acute Coronary Syndrome | Cerebrovascular accident | Transient Ischemic Attack

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0948089
UMLS CUI [2]
C0038454
UMLS CUI [3]
C0007787
indication of liver disease, defined by serum levels of either alanine transaminase (alt), aspartate transaminase (ast), or alkaline phosphatase (alp) above 3 x upper limit of normal (uln)
Descrizione

Indication Liver disease | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C0023895
UMLS CUI [2]
C0151905
UMLS CUI [3]
C0151904
UMLS CUI [4]
C0151849
Ritorna all'inizio della pagina

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT02489968

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosis of type 2 diabetes prior to informed consent
boolean
C0011860 (UMLS CUI [1])
Diet therapy | Exercise
Item
male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are:
boolean
C0012159 (UMLS CUI [1])
C0015259 (UMLS CUI [2])
Antidiabetics Absent
Item
drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
boolean
C0935929 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Antidiabetics Oral Quantity | Sulfonylurea | Antidiabetics Dose Stable | Thiazolidinediones unchanged | Antidiabetics Specific To be stopped
Item
pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of the maximum approved dose) on stable dosage for at least 12 weeks prior to the informed consent (for thiazolidinedione, therapy has to be unchanged for at least 18 weeks prior to the informed consent). individual antidiabetic drug will have to be discontinued at visit 1.
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0038766 (UMLS CUI [2])
C0935929 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
C1257987 (UMLS CUI [4,1])
C0442739 (UMLS CUI [4,2])
C0935929 (UMLS CUI [5,1])
C0205369 (UMLS CUI [5,2])
C1272691 (UMLS CUI [5,3])
Glycosylated hemoglobin A
Item
haemoglobin a1c (hba1c) at visit 1 (screening)
boolean
C0019018 (UMLS CUI [1])
Hemoglobin A1c measurement | Antidiabetics Absent
Item
for patients without antidiabetic therapy : hba1c >=8.0 to =<10.5%
boolean
C0474680 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Hemoglobin A1c measurement | Antidiabetics Oral Quantity
Item
for patients with one oral antidiabetic drug : hba1c >=7.5 to =<10.5%
boolean
C0474680 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Hemoglobin A1c measurement | Randomization Double-Blind Method
Item
hba1c >=7.5 to =<10.0% at visit 4 for randomisation into the double blind treatment period
boolean
C0474680 (UMLS CUI [1])
C0034656 (UMLS CUI [2,1])
C0013072 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Hyperglycemia Uncontrolled | Glucose level
Item
uncontrolled hyperglycaemia with a glucose level >270 mg/dl (>15.0 mmol/l) during the open label stabilisation period and placebo run in period
boolean
C0020456 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0428548 (UMLS CUI [2])
Renal Insufficiency | Renal function GFR estimation by MDRD
Item
impaired renal function, defined as estimated glomerular filtration rate (egfr) <45 ml/min/1.73m2 (modification of diet in renal disease (mdrd) formula)
boolean
C1565489 (UMLS CUI [1])
C2170215 (UMLS CUI [2])
Acute Coronary Syndrome | Cerebrovascular accident | Transient Ischemic Attack
Item
acute coronary syndrome, stroke or transient ischemic attack (tia) within 12 weeks prior to informed consent
boolean
C0948089 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0007787 (UMLS CUI [3])
Indication Liver disease | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised
Item
indication of liver disease, defined by serum levels of either alanine transaminase (alt), aspartate transaminase (ast), or alkaline phosphatase (alp) above 3 x upper limit of normal (uln)
boolean
C3146298 (UMLS CUI [1,1])
C0023895 (UMLS CUI [1,2])
C0151905 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
C0151849 (UMLS CUI [4])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial